Breaking News Instant updates and real-time market news.

MDLZ

Mondelez

$64.46 /

-1.34 (-2.04%)

 15:34
04/26/22
 04/26
15:34
 04/26/22
15:34

Mondelez options imply 3.3% move in share price post-earnings

Pre-earnings options volume in Mondelez is 2.4x normal with puts leading calls 2:1. Implied volatility suggests the market is anticipating a move near 3.3%, or $2.10, after results are released. Median move over the past eight quarters is 1.8%.

  • 26

    Apr

  • 18

    May

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks
Horizon Global announces review of strategic alternatives » 17:46
08/08/22
08/08
17:46
08/08/22
17:46
HZN

Horizon Global

$1.38 /

+0.035 (+2.60%)

Horizon Global announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HZN Horizon Global
$1.38 /

+0.035 (+2.60%)

07/29/22
Horizon Global addresses NYSE continued listing standards
06/29/22
Horizon Global appoints Jian James Zhou as CFO
06/08/22
Horizon Global and Continental settle patent dispute
02/14/22
Horizon Global rises 10.6%
08/09/22
Horizon Global - HZN
Earnings
Cara Therapeutics reports Q2 EPS (8c), consensus (25c) » 17:43
08/08/22
08/08
17:43
08/08/22
17:43
CARA

Cara Therapeutics

$11.50 /

+0.215 (+1.91%)

Reports Q2 revenue $23M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CARA Cara Therapeutics
$11.50 /

+0.215 (+1.91%)

06/30/22
Cara Therapeutics announces results from Phase 2 trial of difelikefalin
06/06/22
Amarin CFO Michael Kalb resigns, Tom Reilly to succeed
06/03/22
Cara Therapeutics CFO Thomas Reilly resigns, Richard Makara named interim CFO
04/28/22
Vifor Fresenius, Cara announces European Commission authorization for Kapruvia
CARA Cara Therapeutics
$11.50 /

+0.215 (+1.91%)

05/10/22 H.C. Wainwright
H.C. Wainwright sees 'major valuation disconnect' at Cara Therapeutics
03/14/22 Canaccord
Cara Therapeutics price target lowered to $29 from $33 at Canaccord
03/08/22 JPMorgan
Cara Therapeutics upgraded to Overweight from Neutral at JPMorgan
11/01/21 Canaccord
Cara Therapeutics assumed with a Buy at Canaccord
CARA Cara Therapeutics
$11.50 /

+0.215 (+1.91%)

05/09/22
Cara Therapeutics reports Q1 EPS (52c), consensus (54c)
03/01/22
Cara Therapeutics reports Q4 EPS (63c), consensus (52c)
00:00 Today
42nd Annual Global I Growth Conference
16:30 Today
Cara Therapeutics - CARA
Earnings
Chimerix reports Q2 EPS (27c), consensus (24c) » 17:36
08/08/22
08/08
17:36
08/08/22
17:36
CMRX

Chimerix

$2.36 /

-0.325 (-12.13%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CMRX Chimerix
$2.36 /

-0.325 (-12.13%)

07:22 Today
Chimerix appoints Jordan as VP, Regulatory Affairs
08/04/22
Siga, Chimerix rallyafter WaPo report of monkeypox emergency declaration
06/24/22
Chimerix announces $25.3M TEMBEXA procurement agreement
06/23/22
Chimerix announces $9.3M TEMBEXA procurement agreement
CMRX Chimerix
$2.36 /

-0.325 (-12.13%)

05/20/22 Benchmark
Benchmark says Emergent, Siga, Chimerix strength attributable to monkeypox scare
05/16/22 H.C. Wainwright
Chimerix price target lowered to $11 from $24 at H.C. Wainwright
12/22/21 H.C. Wainwright
Chimerix price target raised to $24 from $21 at H.C. Wainwright
11/22/21 H.C. Wainwright
Chimerix price target raised to $21 from $19 at H.C. Wainwright
CMRX Chimerix
$2.36 /

-0.325 (-12.13%)

05/16/22
Chimerix reports Q1 EPS (28c), consensus (33c)
03/01/22
Chimerix reports Q4 EPS (45c), consensus (17c)
  • 15
    Sep
CMRX Chimerix
$2.36 /

-0.325 (-12.13%)

08/04/22
Biden to declare monkeypox public health emergency, Washington Post says
07/25/22
WHO declares monkeypox outbreak global health emergency, CNBC reports
CMRX Chimerix
$2.36 /

-0.325 (-12.13%)

08/04/22
What You Missed On Wall Street On Thursday
07/25/22
These vaccine makers are jumping after monkeypox declared global emergency
05/27/22
As Monkeypox cases rise, so do shares of Siga
05/16/22
What You Missed On Wall Street On Monday
08/09/22
Wedbush PacGrow Healthcare Virtual Conference
16:30 Today
Chimerix - CMRX
Hot Stocks
Ur-Energy signs agreement with U.S. nuclear utility » 17:35
08/08/22
08/08
17:35
08/08/22
17:35
URG

Ur-Energy

$1.18 /

-0.01 (-0.84%)

Ur-Energy announce that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
URG Ur-Energy
$1.18 /

-0.01 (-0.84%)

11/02/21 Alliance Global Partners
Ur-Energy price target raised to $2.50 from $2.20 at Alliance Global Partners
URG Ur-Energy
$1.18 /

-0.01 (-0.84%)

04/18/22
Energy Department set to announce $6B nuclear plant lifeline, Bloomberg says
Earnings
Mesa Air reports Q3 EPS (28c), consensus (22c) » 17:34
08/08/22
08/08
17:34
08/08/22
17:34
MESA

Mesa Air

$2.66 /

+0.135 (+5.35%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MESA Mesa Air
$2.66 /

+0.135 (+5.35%)

06/08/22
Mesa Air announces enhanced United Aviate partnership
04/22/22
Mesa Air appoints Amy Krallman as VP, human resources
03/01/22
Mesa Air appoints Christian Daoud as VP, maintenance and technical operations
MESA Mesa Air
$2.66 /

+0.135 (+5.35%)

05/11/22 Deutsche Bank
Mesa Air price target lowered to $3 from $5.50 at Deutsche Bank
02/04/22 Raymond James
Mesa Air downgraded to Market Perform from Outperform at Raymond James
02/04/22 Raymond James
Mesa Air downgraded to Market Perform from Outperform at Raymond James
01/07/22 BofA
Mesa Air downgraded to Neutral from Buy at BofA
MESA Mesa Air
$2.66 /

+0.135 (+5.35%)

05/09/22
Mesa Air reports Q2 EPS ( 29c), consensus (31c)
02/09/22
Mesa Air reports Q EPS (26c), consensus (12c)
16:30 Today
Mesa Air - MESA
Hot Stocks
National Healthcare announces $25M stock repurchase authorization » 17:31
08/08/22
08/08
17:31
08/08/22
17:31
NHC

National Healthcare

$69.31 /

+1.14 (+1.67%)

National HealthCare…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NHC National Healthcare
$69.31 /

+1.14 (+1.67%)

05/05/22
National Healthcare raises quarterly dividend by 3.6% to 57c per share
NHC National Healthcare
$69.31 /

+1.14 (+1.67%)

02/18/22
National Healthcare reports Q4 adjusted EPS $1.02 vs. 90c last year
Hot Stocks
CorMedix receives CRL from FDA saying that DefenCath NDA cannot be approved » 17:31
08/08/22
08/08
17:31
08/08/22
17:31
CRMD

CorMedix

$7.50 /

+0.39 (+5.49%)

CorMedix announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRMD CorMedix
$7.50 /

+0.39 (+5.49%)

05/12/22
CorMedix believes it has sufficient resources to fund through 1H of 2023
05/12/22
CorMedix announces leadership updates, operational changes
04/07/22
CorMedix announces SAB to support commercialization, pipeline development
03/28/22
CorMedix announces FDA acceptance of resubmission of NDA for DefenCath
CRMD CorMedix
$7.50 /

+0.39 (+5.49%)

05/12/22
CorMedix reports Q1 EPS (18c), consensus (22c)
03/29/22
CorMedix reports Q4 EPS (20c), consensus (23c)
CRMD CorMedix
$7.50 /

+0.39 (+5.49%)

03/29/22
Fly Intel: After-Hours Movers
08/11/22
CorMedix - CRMD
Syndicate
Cyteir Therapeutics files $300M mixed securities shelf  17:30
08/08/22
08/08
17:30
08/08/22
17:30
CYT

Cyteir Therapeutics

$2.58 /

+0.09 (+3.61%)

 
ShowHide Related Items >><<
CYT Cyteir Therapeutics
$2.58 /

+0.09 (+3.61%)

16:08 Today
Cyteir Therapeutics expects cash to fund operations into second half of 2024
06/05/22
Cyteir Therapeutics presents CYT-0851 Phase 1 dose escalation results
04/25/22
Cyteir Therapeutics appoints Adam Veness as general counsel
CYT Cyteir Therapeutics
$2.58 /

+0.09 (+3.61%)

03/17/22 Wedbush
Cyteir Therapeutics price target lowered to $30 from $40 at Wedbush
02/07/22 Northland
Cyteir Therapeutics initiated with an Outperform at Northland
CYT Cyteir Therapeutics
$2.58 /

+0.09 (+3.61%)

16:08 Today
Cyteir Therapeutics reports Q2 EPS (34c), consensus (44c)
05/05/22
Cyteir Therapeutics reports Q1 EPS (40c), consensus (39c)
03/16/22
Cyteir Therapeutics reports Q4 EPS (34c), consensus (39c)
00:00 Today
Biotechnology Conference
08/09/22
Wedbush PacGrow Healthcare Virtual Conference
Syndicate
Biolase files to sell 1.41M shares of common stock for holders  17:30
08/08/22
08/08
17:30
08/08/22
17:30
BIOL

Biolase

$5.40 /

+0.12 (+2.27%)

 
ShowHide Related Items >><<
BIOL Biolase
$5.40 /

+0.12 (+2.27%)

07/25/22
Biolase receives five new United States patents, seven new foreign patents
07/13/22
Biolase announces pilot program with Einstein Healthcare Network's residency
07/07/22
Biolase promotes Jennifer Bright to CFO, Steven Sandor to COO
07/05/22
Biolase announces partnership with TeamSmile
BIOL Biolase
$5.40 /

+0.12 (+2.27%)

05/20/22 Lake Street
Biolase initiated with a Buy at Lake Street
08/19/21 Ascendiant
Biolase price target raised to $3 from $2 at Ascendiant
BIOL Biolase
$5.40 /

+0.12 (+2.27%)

05/12/22
Biolase sees Q2 revenue above $10.5M, consensus $10.2M
05/12/22
Biolase reports Q1 EPS (77c), consensus (68c)
08/11/22
Biolase - BIOL
Syndicate
CinCor Pharma files to sell 6M shares of common stock, pre-funded warrants » 17:29
08/08/22
08/08
17:29
08/08/22
17:29
CINC

CinCor Pharma

$34.96 /

+11.46 (+48.77%)

Goldman Sachs & Co.,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CINC CinCor Pharma
$34.96 /

+11.46 (+48.77%)

07:24 Today
CinCor Pharma announces data for Phase 2 BrigHtn trial evaluating baxdrostat
07:21 Today
CinCor Pharma announces upcoming milestones
07/26/22
CinCor Pharma announces last patient randomized in Phase 2 HALO trial
06/01/22
CinCor Pharma doses first patient in Phase 2 figHTN-CKD trial
CINC CinCor Pharma
$34.96 /

+11.46 (+48.77%)

14:35 Today Oppenheimer
CinCor Pharma price target raised to $60 from $35 at Oppenheimer
07/21/22 Oppenheimer
CinCor Pharma price target raised to $35 from $30 at Oppenheimer
02/01/22 Oppenheimer
CinCor Pharma initiated with an Outperform at Oppenheimer
02/01/22 Evercore ISI
CinCor Pharma initiated with an Outperform at Evercore ISI
CINC CinCor Pharma
$34.96 /

+11.46 (+48.77%)

07:20 Today
CinCor Pharma reports Q2 EPS (56c), consensus (50c)
05/10/22
CinCor Pharma reports Q1 EPS (50c), consensus (50c)
03/22/22
CinCor Pharma reports Q4 EPS ($15.71) vs. ($4.65) last year
  • 07
    Jan
CINC CinCor Pharma
$34.96 /

+11.46 (+48.77%)

16:46 Today
What You Missed On Wall Street On Monday
12:12 Today
What You Missed On Wall Street This Morning
03/26/22
Opening Day: AN2 Therapeutics rises in public debut after upsized IPO
08:30 Today
CinCor Pharma - CINC
CINC CinCor Pharma
$34.96 /

+11.46 (+48.77%)

07/13/22
Two new option listings on July 13th
Earnings
Primoris reports Q2 adjusted EPS 48c, two estimates 59c » 17:29
08/08/22
08/08
17:29
08/08/22
17:29
PRIM

Primoris

$22.52 /

+0.095 (+0.42%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PRIM Primoris
$22.52 /

+0.095 (+0.42%)

07/05/22
Primoris awarded contract at over $170M
06/27/22
Primoris enter agreement to acquire PLH in all-cash transaction valued at $470M
06/23/22
Primoris awarded $260M solar project
05/06/22
Primoris awarded $130M solar project
PRIM Primoris
$22.52 /

+0.095 (+0.42%)

11/10/21 Goldman Sachs
Goldman downgrades Primoris to Sell on 'bottom quintile' growth
11/10/21 Goldman Sachs
Primoris downgraded to Sell from Neutral at Goldman Sachs
PRIM Primoris
$22.52 /

+0.095 (+0.42%)

05/09/22
Primoris raises FY22 adjusted EPS view to $2.49-$2.69 from $2.39-$2.59
05/09/22
Primoris reports Q1 adjusted EPS 1c, consensus 9c
02/28/22
Primoris sees FY22 EPS $2.39-$2.59, consensus $2.50
02/28/22
Primoris reports Q4 EPS 63c, consensus 56c
08/09/22
Primoris - PRIM
Syndicate
Merchants Bancorp files $500M mixed securities shelf  17:27
08/08/22
08/08
17:27
08/08/22
17:27
MBIN

Merchants Bancorp

$27.72 /

+0.445 (+1.63%)

 
ShowHide Related Items >><<
MBIN Merchants Bancorp
$27.72 /

+0.445 (+1.63%)

02/17/22
Merchants Bancorp raises quarterly dividend 17% to 7c from 6c per share
MBIN Merchants Bancorp
$27.72 /

+0.445 (+1.63%)

04/28/22
Merchants Bancorp reports Q1 EPS $1.02, consensus $1.00
Earnings
Freshpet backs FY22 revenue view of at least $575M, consensus $582.72M » 17:27
08/08/22
08/08
17:27
08/08/22
17:27
FRPT

Freshpet

$56.39 /

+1.895 (+3.48%)

Sees FY22 adjusted EBITDA…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FRPT Freshpet
$56.39 /

+1.895 (+3.48%)

06/22/22
Freshpet recalls select product due to potential Salmonella contamination
FRPT Freshpet
$56.39 /

+1.895 (+3.48%)

05/20/22 Atlantic Equities
Atlantic Equities sees more volatility for Freshpet, downgrades shares
05/20/22 Atlantic Equities
Freshpet downgraded to Neutral from Overweight at Atlantic Equities
05/03/22 Cowen
Freshpet price target lowered to $163 from $181 at Cowen
05/03/22 Oppenheimer
Freshpet price target lowered to $110 from $120 at Oppenheimer
FRPT Freshpet
$56.39 /

+1.895 (+3.48%)

17:25 Today
Freshpet reports Q2 EPS (45c), consensus (14c)
05/02/22
Freshpet backs FY22 revenue view at least $575M, consensus $576.99M
05/02/22
Freshpet reports Q1 EPS (40c), consensus (39c)
02/28/22
Freshpet sees FY22 revenue $575M, consensus $562.4M
  • 04
    May
FRPT Freshpet
$56.39 /

+1.895 (+3.48%)

05/20/22
Proven algorithm says sell these stocks now
05/20/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
05/13/22
Short Report: Upstart shorts take profits as stock craters on guidance cut
05/13/22
Proven algorithm says sell these stocks now
16:30 Today
Freshpet - FRPT
08/11/22
Freshpet
Syndicate
Rallybio files $300M mixed securities shelf  17:25
08/08/22
08/08
17:25
08/08/22
17:25
RLYB

Rallybio

$10.61 /

-0.54 (-4.84%)

 
ShowHide Related Items >><<
RLYB Rallybio
$10.61 /

-0.54 (-4.84%)

06/02/22
Rallybio announces Jeffrey Fryer to retire from CFO position
05/25/22
Rallybio director sold $1.3M in common stock
05/10/22
Rallybio announces in-licensing of Sanofi's KY1066
RLYB Rallybio
$10.61 /

-0.54 (-4.84%)

02/22/22 JMP Securities
Rallybio initiated with an Outperform at JMP Securities
08/23/21 Evercore ISI
Rallybio initiated with an Outperform at Evercore ISI
08/23/21 Cowen
Rallybio initiated with an Outperform at Cowen
08/23/21 Jefferies
Rallybio initiated with a Buy at Jefferies
RLYB Rallybio
$10.61 /

-0.54 (-4.84%)

05/10/22
Rallybio reports Q1 EPS (48c), consensus (45c)
03/15/22
Rallybio reports Q4 EPS (42c), consensus (39c)
Earnings
Freshpet reports Q2 EPS (45c), consensus (14c) » 17:25
08/08/22
08/08
17:25
08/08/22
17:25
FRPT

Freshpet

$56.39 /

+1.895 (+3.48%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FRPT Freshpet
$56.39 /

+1.895 (+3.48%)

06/22/22
Freshpet recalls select product due to potential Salmonella contamination
FRPT Freshpet
$56.39 /

+1.895 (+3.48%)

05/20/22 Atlantic Equities
Atlantic Equities sees more volatility for Freshpet, downgrades shares
05/20/22 Atlantic Equities
Freshpet downgraded to Neutral from Overweight at Atlantic Equities
05/03/22 Cowen
Freshpet price target lowered to $163 from $181 at Cowen
05/03/22 Oppenheimer
Freshpet price target lowered to $110 from $120 at Oppenheimer
FRPT Freshpet
$56.39 /

+1.895 (+3.48%)

05/02/22
Freshpet backs FY22 revenue view at least $575M, consensus $576.99M
05/02/22
Freshpet reports Q1 EPS (40c), consensus (39c)
02/28/22
Freshpet sees FY22 revenue $575M, consensus $562.4M
02/28/22
Freshpet reports Q4 EPS (21c), consensus (16c)
  • 04
    May
FRPT Freshpet
$56.39 /

+1.895 (+3.48%)

05/20/22
Proven algorithm says sell these stocks now
05/20/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
05/13/22
Short Report: Upstart shorts take profits as stock craters on guidance cut
05/13/22
Proven algorithm says sell these stocks now
16:30 Today
Freshpet - FRPT
08/11/22
Freshpet
Conference/Events
CTI BioPharma management to meet virtually with BTIG » 17:25
08/08/22
08/08
17:25
08/08/22
17:25
CTIC

CTI BioPharma

$7.04 /

-0.38 (-5.12%)

In conjunction with the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CTIC CTI BioPharma
$7.04 /

-0.38 (-5.12%)

06/10/22
CTI BioPharma presents data from pacritinib program at EHA
05/26/22
CTI BioPharma to present pivotal data on pacritinib program
04/14/22
CTI BioPharma's Vonjo included in NCCN Myeloproliferative Neoplasm guidelines
02/28/22
CTI BioPharma announces FDA accelerated approval of VONJO
CTIC CTI BioPharma
$7.04 /

-0.38 (-5.12%)

11:28 Today Stifel
Global Blood Therapeutics downgraded to Hold from Buy at Stifel
07/07/22 Cowen
Cowen starts CTI BioPharma at Outperform on 'high growth opportunity'
07/07/22 Cowen
CTI BioPharma initiated with an Outperform at Cowen
04/14/22 Stifel
Stifel reiterates Buy on CTI BioPharma following new treatment guidelines
CTIC CTI BioPharma
$7.04 /

-0.38 (-5.12%)

16:30 Today
CTI BioPharma reports Q2 EPS (21c), consensus (20c)
05/12/22
CTI BioPharma reports Q1 EPS (23c), consensus (41c)
03/31/22
CTI BioPharma reports Q4 EPS (38c), consensus (28c)
CTIC CTI BioPharma
$7.04 /

-0.38 (-5.12%)

06/27/22
Fly Insider: American Woodmark, Coursera among week's notable insider trades
05/13/22
What You Missed On Wall Street On Friday
05/13/22
What You Missed On Wall Street This Morning
04/01/22
What You Missed On Wall Street On Friday
00:00 Today
Biotechnology Conference
08/15/22
2022 Biotech Summer Summit
08/09/22
CTI BioPharma - CTIC
CTIC CTI BioPharma
$7.04 /

-0.38 (-5.12%)

05/12/22
CTI BioPharma options imply 10.5% move in share price post-earnings
04/18/22
Unusually active option classes on open April 18th
03/31/22
CTI BioPharma options imply 5.3% move in share price post-earnings
03/24/22
CTI BioPharma options imply 7.9% move in share price post-earnings
Conference/Events
Legend Biotech management to meet with BTIG » 17:25
08/08/22
08/08
17:25
08/08/22
17:25
LEGN

Legend Biotech

$49.50 /

-0.385 (-0.77%)

BTIG Biotechnology…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LEGN Legend Biotech
$49.50 /

-0.385 (-0.77%)

06/05/22
Legend Biotech presents results from CARTITUDE clinical development program
06/03/22
Legend Biotech announces FDA clearance of LB1908 IND application
05/26/22
Legend Biotech granted conditional marketing authorization for Carvykti by EC
05/09/22
Legend Biotech names Lori Macomber as CFO, effective immediately
LEGN Legend Biotech
$49.50 /

-0.385 (-0.77%)

07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
06/16/22 BMO Capital
Legend Biotech initiated with an Outperform at BMO Capital
05/31/22 Morgan Stanley
Legend Biotech named Catalyst Driven Idea by Morgan Stanley
03/15/22 Barclays
Legend Biotech initiated with an Overweight at Barclays
LEGN Legend Biotech
$49.50 /

-0.385 (-0.77%)

06/01/22
Legend Biotech reports Q1 EPS (13c), consensus (46c)
03/18/22
Legend Biotech reports Q4 EPS (30c), consensus (41c)
  • 27
    Jul
  • 16
    Dec
LEGN Legend Biotech
$49.50 /

-0.385 (-0.77%)

03/07/22
Johnson & Johnson negotiating deals with two Chinese companies, FT reports
LEGN Legend Biotech
$49.50 /

-0.385 (-0.77%)

07/25/22
Fly Intel: After-Hours Movers
07/20/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
06/17/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
18:30 Today
Legend Biotech
Conference/Events
Liquidia Technologies management to meet with BTIG » 17:25
08/08/22
08/08
17:25
08/08/22
17:25
LQDA

Liquidia Technologies

$5.35 /

-0.01 (-0.19%)

In conjunction with the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LQDA Liquidia Technologies
$5.35 /

-0.01 (-0.19%)

08/01/22
Liquidia announces publication of long-term clinical data from INSPIRE study
07/25/22
Liquidia reports inducement grant under Nasdaq listing rule
07/19/22
Liquidia Technologies receives favorable ruling in IPR against UTC patent
07/19/22
USPTO says Liquidia established United Therapeutics' '793 patent 'unpatentable'
LQDA Liquidia Technologies
$5.35 /

-0.01 (-0.19%)

07/22/22 Ladenburg
Ladenburg starts Liquidia Technologies at Buy with $15 price target
07/22/22 Ladenburg
Liquidia Technologies initiated with a Buy at Ladenburg
07/20/22 BTIG
Liquidia Technologies price target raised to $17 from $14 at BTIG
05/31/22 BTIG
Liquidia Technologies initiated with a Buy at BTIG
LQDA Liquidia Technologies
$5.35 /

-0.01 (-0.19%)

05/12/22
Liquidia Technologies reports Q1 EPS (30c) vs. (21c) last year
  • 15
    Apr
LQDA Liquidia Technologies
$5.35 /

-0.01 (-0.19%)

07/22/22
What You Missed On Wall Street On Friday
07/22/22
What You Missed On Wall Street This Morning
07/22/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
04/13/22
What You Missed On Wall Street On Wednesday
08/11/22
Liquidia Technologies - LQDA
18:00 Today
Liquidia Technologies
Conference/Events
Andersons management to meet with Stephens » 17:25
08/08/22
08/08
17:25
08/08/22
17:25
ANDE

Andersons

$37.90 /

-0.05 (-0.13%)

Stephens holds a group…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ANDE Andersons
$37.90 /

-0.05 (-0.13%)

05/03/22
Andersons signs agreement to sell its railcar repair business
ANDE Andersons
$37.90 /

-0.05 (-0.13%)

05/05/22 BMO Capital
Andersons price target lowered to $45 from $50 at BMO Capital
03/25/22 Lake Street
Andersons price target raised to $60 from $50 at Lake Street
02/17/22 Lake Street
Andersons price target raised to $50 from $45 at Lake Street
11/29/21 Lake Street
Andersons price target raised to $45 from $42 at Lake Street
ANDE Andersons
$37.90 /

-0.05 (-0.13%)

08/02/22
Andersons reports Q2 adjusted EPS $2.39, consensus 98c
05/03/22
Andersons reports Q1 adjusted EPS 18c vs. 35c a year ago
02/15/22
Andersons reports Q4 adjusted EPS $1.14, consensus 66c
09/14/22
6th Annual Best Ideas Growth Conference: Big 6
18:00 Today
Andersons
Syndicate
Cybin announces at-the-market equity program for up to $35M » 17:23
08/08/22
08/08
17:23
08/08/22
17:23
CYBN

Cybin

/

+

Cybin "announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CYBN Cybin
/

+

07/12/22
Cybin begins trial enrollment for CYB003 study for MDD treatment
06/27/22
Cybin announces additional Adelia milestone achievement
06/27/22
Cybin receives FDA IND clearance for Phase 1/2a trial evaluating CYB003
06/09/22
Cybin gets IRB approval for Phase 1/2a clinical trial of CYB003 in MDD
CYBN Cybin
/

+

06/23/22 Canaccord
Cybin undervalued relative to market size opportunity, says Canaccord
06/10/22 Canaccord
Cybin shares remain significantly undervalued, says Canaccord
04/13/22 H.C. Wainwright
H.C. Wainwright says Cybin preclinical data show continued innovation leadership
11/23/21 Stifel
Cybin price target lowered to C$8.25 from C$10 at Stifel
CYBN Cybin
/

+

17:10 Today
Cybin reports Q1 cash, cash equivalents C$42.5M
00:00 Today
42nd Annual Global I Growth Conference
Hot Stocks
Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056 » 17:22
08/08/22
08/08
17:22
08/08/22
17:22
MRSN

Mersana Therapeutics

$5.24 /

+0.215 (+4.28%)

, GSK

GSK plc

$40.31 /

-0.27 (-0.67%)

Mersana Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$5.24 /

+0.215 (+4.28%)

16:35 Today
Mersana Therapeutics trading resumes
16:00 Today
Mersana Therapeutics trading halted, news pending
05/23/22
Mersana Therapeutics director Hack buys 216K shares of stock
05/19/22
Mersana announces FDA grant of orphan drug designation to XMT-2056
GSK GSK plc
$40.31 /

-0.27 (-0.67%)

10:43 Today
GSK, IQVIA launch Vaccine Track platform
07/29/22
ViiV Healthcare presents five-year data at AIDS 2022 on fostemsavir
07/28/22
ViiV Healthcare announces data from unblinded phase of HPTN 084 study
07/28/22
GSK plc signs framework contract with EC for supply of Adjupanrix flu vaccine
MRSN Mersana Therapeutics
$5.24 /

+0.215 (+4.28%)

05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
05/09/22 H.C. Wainwright
Mersana price target lowered to $19 from $24 at H.C. Wainwright
11/10/21 Baird
Mersana Therapeutics price target lowered to $23 from $30 at Baird
10/14/21 BTIG
Mersana Therapeutics assumed with a Buy at BTIG
GSK GSK plc
$40.31 /

-0.27 (-0.67%)

14:58 Today UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
08/05/22 Morgan Stanley
GSK plc resumed with an Equal Weight at Morgan Stanley
07/21/22 Citi
GSK plc resumed with a Neutral at Citi
07/20/22 UBS
GSK plc price target lowered to 1,850 GBp from 1,876 GBp at UBS
MRSN Mersana Therapeutics
$5.24 /

+0.215 (+4.28%)

16:24 Today
Mersana Therapeutics reports Q2 EPS (55c), consensus (52c)
05/09/22
Mersana Therapeutics reports Q1 EPS (59c), consensus (32c)
02/28/22
Mersana Therapeutics reports Q4 EPS (68c), consensus (67c)
GSK GSK plc
$40.31 /

-0.27 (-0.67%)

07/27/22
GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year
04/27/22
GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER
04/27/22
GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year
04/13/22
GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B
GSK GSK plc
$40.31 /

-0.27 (-0.67%)

07/18/22
GSK CEO says split will help deal with 'perennial underperformance,' FT reports
06/27/22
GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says
06/27/22
GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says
06/06/22
GSK rectal cancer trial yields remission in all 18 patients, NY Times reports
MRSN Mersana Therapeutics
$5.24 /

+0.215 (+4.28%)

04/14/22
What You Missed On Wall Street This Morning
02/09/22
Wall Street in Fives - Must Read Lists for Wednesday
02/09/22
Wall Street in Fives - Must Read Lists at Midday
GSK GSK plc
$40.31 /

-0.27 (-0.67%)

08/05/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
07/18/22
What You Missed On Wall Street This Morning
07/18/22
Fly Intel: Pre-market Movers
06/24/22
What You Missed On Wall Street On Friday
06/08/22
Global Healthcare Conference
08/09/22
Wedbush PacGrow Healthcare Virtual Conference
09/10/22
ESMO Congress 2022
16:30 Today
Mersana Therapeutics - MRSN
GSK GSK plc
$40.31 /

-0.27 (-0.67%)

07/29/22
GSK plc (ADR) call volume above normal and directionally bullish
07/22/22
Two new option listings and one option delisting on July 22nd
07/20/22
One new option listing and two option delistings on July 20th
07/08/22
GlaxoSmithKline call volume above normal and directionally bullish
Syndicate
Canoo files automatic mixed securities shelf  17:22
08/08/22
08/08
17:22
08/08/22
17:22
GOEV

Canoo

$3.95 /

+0.26 (+7.05%)

 
ShowHide Related Items >><<
GOEV Canoo
$3.95 /

+0.26 (+7.05%)

16:52 Today
Canoo sees second half of FY22 operating expenses $200M-$245M
07/14/22
Canoo's multi-purpose platform selected by Army for analysis & demostration
07/13/22
Canoo drops 5% after disclosing Walmart pact prevents sales to Amazon
07/13/22
Canoo says Walmart agreement prevents sales to Amazon
GOEV Canoo
$3.95 /

+0.26 (+7.05%)

07/14/22 R.F. Lafferty
Canoo price target lowered to $17 from $20 at R.F. Lafferty
07/13/22 H.C. Wainwright
Canoo price target lowered to $10 from $15 at H.C. Wainwright
12/16/21 R.F. Lafferty
Canoo price target raised to $21 from $19 at R.F. Lafferty
12/16/21 Roth Capital
Roth Capital upgrades Canoo to Buy, raises price target to $14
GOEV Canoo
$3.95 /

+0.26 (+7.05%)

16:51 Today
Canoo reports Q2 EPS (68c), consensus (53c)
05/10/22
Canoo reports Q1 EPS (54c), consensus (50c)
02/28/22
Canoo reports Q4 EPS (60c), consensus (51c)
GOEV Canoo
$3.95 /

+0.26 (+7.05%)

02/11/22
Canoo has lost founders, key engineers post-SPAC, Business Insider reports
GOEV Canoo
$3.95 /

+0.26 (+7.05%)

07/25/22
Fly Insider: CrossFirst Bankshares, Canoo among week's notable insider trades
07/23/22
Short Report: Revlon shorts recede, stock retreats as buyout news fades
07/18/22
What You Missed This Week in EVs and Clean Energy
07/16/22
Short Report: Canoo shorts going along for the ride
17:00 Today
Canoo - GOEV
GOEV Canoo
$3.95 /

+0.26 (+7.05%)

13:19 Today
Canoo options imply 15.3% move in share price post-earnings
07/27/22
Largest borrow rate increases among liquid names
07/20/22
Largest borrow rate increases among liquid names
07/14/22
Unusually active option classes on open July 14th
Earnings
Aterian reports Q2 EPS (26), consensus (12c) » 17:22
08/08/22
08/08
17:22
08/08/22
17:22
ATER

Aterian

$2.97 /

+0.225 (+8.20%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ATER Aterian
$2.97 /

+0.225 (+8.20%)

04/18/22
Aterian appoints Anton von Rueden as COO
04/01/22
Aterian appoints Cynthia Williams to board of directorsHasbro
03/02/22
Aterian announces pricing of $27.5M private placement
ATER Aterian
$2.97 /

+0.225 (+8.20%)

03/11/22 Alliance Global Partners
Aterian price target lowered to $4.50 from $9 at Alliance Global Partners
03/09/22 BTIG
Aterian price target lowered to $5 from $9 at BTIG
03/09/22 DA Davidson
Aterian price target lowered to $7 from $14 at DA Davidson
02/11/22 Alliance Global Partners
Aterian price target lowered to $9 from $13 at Alliance Global Partners
ATER Aterian
$2.97 /

+0.225 (+8.20%)

05/09/22
Aterian reports Q1 EPS (78c), consensus (25c)
03/08/22
Aterian reports Q4 EPS (11c), consensus (12c)
ATER Aterian
$2.97 /

+0.225 (+8.20%)

05/10/22
Fly Intel: Pre-market Movers
05/09/22
Fly Intel: After-Hours Movers
04/18/22
What You Missed On Wall Street On Monday
04/18/22
What You Missed On Wall Street This Morning
17:00 Today
Aterian - ATER
ATER Aterian
$2.97 /

+0.225 (+8.20%)

15:04 Today
Aterian options imply 16.3% move in share price post-earnings
06/09/22
Largest borrow rate increases among liquid names
05/25/22
Largest borrow rate increases among liquid names
05/20/22
Largest borrow rate increases among liquid names
Earnings
Granite Point Mortgage reports Q2 EPS 22c, consensus 22c » 17:21
08/08/22
08/08
17:21
08/08/22
17:21
GPMT

Granite Point Mortgage

$10.43 /

+0.1 (+0.97%)

Jack Taylor, President,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
08/09/22
Granite Point Mortgage - GPMT
Earnings
Inhibrx reports Q2 EPS (97c), consensus (78c) » 17:21
08/08/22
08/08
17:21
08/08/22
17:21
INBX

Inhibrx

$24.67 /

+1.56 (+6.75%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
INBX Inhibrx
$24.67 /

+1.56 (+6.75%)

06/30/22
Inhibrx completes Phase 1 dose escalation for INBRX-105, draws $60M loan
05/16/22
Inhibrx's INBRX-101 shows favorable safety profile in Phase 1 AATD trial
04/25/22
Inhibrx announces formation of Scientific Advisory Board for INBRX-101
03/03/22
Inhibrx's INBRX-101 granted FDA Orphan-Drug Designation
INBX Inhibrx
$24.67 /

+1.56 (+6.75%)

03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
11/10/21 Credit Suisse
Inhibrx price target raised to $53 from $44 at Credit Suisse
11/02/21 JMP Securities
Inhibrx price target raised to $53 from $46 at JMP Securities
INBX Inhibrx
$24.67 /

+1.56 (+6.75%)

05/09/22
Inhibrx reports Q1 EPS (80c), consensus (60c)
02/28/22
Inhibrx reports Q4 EPS (55c), consensus (57c)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.